Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBITDA (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBITDA for 16 consecutive years, with $272000.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 101.19% to $272000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.1 million through Dec 2025, up 84.17% year-over-year, with the annual reading at -$9.1 million for FY2025, 84.17% up from the prior year.
  • EBITDA for Q4 2025 was $272000.0 at Anika Therapeutics, up from -$2.5 million in the prior quarter.
  • The five-year high for EBITDA was $6.7 million in Q2 2021, with the low at -$62.4 million in Q4 2023.
  • Average EBITDA over 5 years is -$8.0 million, with a median of -$3.8 million recorded in 2022.
  • The sharpest move saw EBITDA soared 189.75% in 2021, then tumbled 1518.55% in 2023.
  • Over 5 years, EBITDA stood at -$6.2 million in 2021, then skyrocketed by 37.76% to -$3.9 million in 2022, then crashed by 1518.55% to -$62.4 million in 2023, then soared by 63.21% to -$22.9 million in 2024, then skyrocketed by 101.19% to $272000.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $272000.0, -$2.5 million, and -$2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.